Skip to main content
logo
Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
23.02
-1.33 (-5.46%)
Jul 31, 2026, 4:00 PM EDT - Market closed

Denali Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---330.53--
Revenue Growth
------
Gross Profit
---330.53--
Selling, General & Admin
140.72136.56105.44103.3590.4879.06
Research & Development
406.4418.78396.44423.88358.73265.35
Other Operating Expenses
---14.54---
Total Operating Expenses
547.12555.34487.34527.23449.21344.41
Operating Income
-547.12-555.34-487.34-196.7-340.74-295.75
Interest Income
39.242.964.6451.5114.774.6
Total Non-Operating Income (Expense)
39.242.964.6451.5114.774.6
Pretax Income
-507.92-512.44-422.71-145.19-325.97-291.16
Provision for Income Taxes
-0.10.070.030.02-0.58
Net Income
-508.02-512.54-422.77-145.22-325.99-290.58
Net Income to Common
-508.02-512.54-422.77-145.22-325.99-290.58
Net Income Growth
------
Shares Outstanding (Basic)
176173164137126122
Shares Outstanding (Diluted)
176173164137126122
Shares Change
3.88%4.97%19.73%9.43%3.30%7.83%
EPS (Basic)
-2.88-2.97-2.57-1.06-2.60-2.39
EPS (Diluted)
-2.88-2.97-2.57-1.06-2.60-2.39
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-419.23-422.1-363.61-370.93-262.55-219.89
Free Cash Flow Growth
------
Free Cash Flow Per Share
-2.38-2.44-2.21-2.70-2.09-1.81
Gross Margin
---100.00%--
Operating Margin
----59.51%--
Profit Margin
----43.94%--
FCF Margin
----112.22%--
EBITDA
-535.42-544.16-479.55-179.97-330.36-287.16
EBITDA Margin
----54.45%--
EBIT
-547.12-555.34-487.34-196.7-340.74-295.75
EBIT Margin
----59.51%--
Effective Tax Rate
--0.02%-0.02%-0.02%-0.01%0.20%
SEC Filings: 10-K · 10-Q